PDCD1 and myeloid sarcoma: Furthermore, ex vivo functional assessments of Th17 and Th1 clones from MS patients revealed that Th17 cells are less susceptible to suppression and have a higher proliferative capacity, which could be attributed to increased expression of co-stimulatory molecules, namely PD-1, in Th17 cells compared to Th1 cells [20].